TY - JOUR
T1 - Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter
AU - Baillat, D.
AU - Leprivier, G.
AU - Régnier, D.
AU - Vintonenko, N.
AU - Bègue, A.
AU - Stéhelin, D.
AU - Aumercier, M.
N1 - Funding Information:
We thank Drs J Coll and Y Rouillé for generous gift of pSUPER constructs, Dr D Tulasne for practical guidance and C Lagrou for technical assistance. We are grateful to Dr V Fafeur and Dr V Mattot for providing pCDNA3-Ets-1dn construct. This work was supported by a grant from the Comité du Nord de la Ligue contre le Cancer. The Ligue Nationale contre le Cancer provided student fellowships for David Baillat and Gabriel Leprivier and a postdoctoral fellowship for Dr Nadejda Vintonenko.
PY - 2006/9/21
Y1 - 2006/9/21
N2 - Regulation of the gene expression of Stromelysin-1 (matrix metalloproteinase-3), a member of the matrix metalloproteinase family, is critical for tissue homeostasis. The Stromelysin-1 promoter is known to be transactivated by Ets proteins through palindromic head-to-head Ets binding sites (EBS), an unusual configuration among metalloproteinase promoters. Patterns of increased co-expression of Stromelysin-1 and Ets-1 genes have been observed in pathological processes such as rheumatoid arthritis, glomerulonephritis and tumor invasion. In this context, we show in a synovial fibroblastic model cell line (HIG-82), which is able to co-express Stromelysin-1 and Ets-1, that the EBS palindrome is essential for the expression of Stromelysin-1. More precisely, using electrophoretic mobility shift assays, DNA affinity purification and chromatin immunoprecipitation, we demonstrate that endogenous Ets-1, but not Ets-2, is present on this palindrome. The use of a dominant-negative form of Ets-1 and the decrease of Ets-1 amount either by fumagillin, an antiangiogenic compound, or by short interfering RNA show that the activation rate of the promoter and the expression of Stromelysin-1 correlate with the level of endogenous Ets-1. Thus, it is the first demonstration, using this cellular model, that endogenously expressed Ets-1 is actually a main activator of the Stromelysin-1 promoter through its effective binding to the EBS palindrome.
AB - Regulation of the gene expression of Stromelysin-1 (matrix metalloproteinase-3), a member of the matrix metalloproteinase family, is critical for tissue homeostasis. The Stromelysin-1 promoter is known to be transactivated by Ets proteins through palindromic head-to-head Ets binding sites (EBS), an unusual configuration among metalloproteinase promoters. Patterns of increased co-expression of Stromelysin-1 and Ets-1 genes have been observed in pathological processes such as rheumatoid arthritis, glomerulonephritis and tumor invasion. In this context, we show in a synovial fibroblastic model cell line (HIG-82), which is able to co-express Stromelysin-1 and Ets-1, that the EBS palindrome is essential for the expression of Stromelysin-1. More precisely, using electrophoretic mobility shift assays, DNA affinity purification and chromatin immunoprecipitation, we demonstrate that endogenous Ets-1, but not Ets-2, is present on this palindrome. The use of a dominant-negative form of Ets-1 and the decrease of Ets-1 amount either by fumagillin, an antiangiogenic compound, or by short interfering RNA show that the activation rate of the promoter and the expression of Stromelysin-1 correlate with the level of endogenous Ets-1. Thus, it is the first demonstration, using this cellular model, that endogenously expressed Ets-1 is actually a main activator of the Stromelysin-1 promoter through its effective binding to the EBS palindrome.
KW - Ets-1
KW - Gene regulation
KW - MMP-3
KW - Synovial fibroblasts cell transcription
UR - http://www.scopus.com/inward/record.url?scp=33748941411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748941411&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1209583
DO - 10.1038/sj.onc.1209583
M3 - Article
C2 - 16652151
AN - SCOPUS:33748941411
SN - 0950-9232
VL - 25
SP - 5764
EP - 5776
JO - Oncogene
JF - Oncogene
IS - 42
ER -